155 related articles for article (PubMed ID: 37528866)
1. Optimizing and developing a scalable, chemically defined, animal component-free lentiviral vector production process in a fixed-bed bioreactor.
Fiol CR; Collignon ML; Welsh J; Rafiq QA
Mol Ther Methods Clin Dev; 2023 Sep; 30():221-234. PubMed ID: 37528866
[TBL] [Abstract][Full Text] [Related]
2. Lentiviral Vector Production from a Stable Packaging Cell Line Using a Packed Bed Bioreactor.
Powers AD; Drury JE; Hoehamer CF; Lockey TD; Meagher MM
Mol Ther Methods Clin Dev; 2020 Dec; 19():1-13. PubMed ID: 32995355
[TBL] [Abstract][Full Text] [Related]
3. Development and Optimization of AAV hFIX Particles by Transient Transfection in an iCELLis(®) Fixed-Bed Bioreactor.
Powers AD; Piras BA; Clark RK; Lockey TD; Meagher MM
Hum Gene Ther Methods; 2016 Jun; 27(3):112-21. PubMed ID: 27229773
[TBL] [Abstract][Full Text] [Related]
4. Optimization of lentiviral vector production for scale-up in fixed-bed bioreactor.
Valkama AJ; Leinonen HM; Lipponen EM; Turkki V; Malinen J; Heikura T; Ylä-Herttuala S; Lesch HP
Gene Ther; 2018 Jan; 25(1):39-46. PubMed ID: 29345252
[TBL] [Abstract][Full Text] [Related]
5. Continuous manufacturing of lentiviral vectors using a stable producer cell line in a fixed-bed bioreactor.
Stibbs DJ; Silva Couto P; Takeuchi Y; Rafiq QA; Jackson NB; Rayat ACME
Mol Ther Methods Clin Dev; 2024 Mar; 32(1):101209. PubMed ID: 38435128
[TBL] [Abstract][Full Text] [Related]
6. Quasi-perfusion studies for intensified lentiviral vector production using a continuous stable producer cell line.
Stibbs DJ; Silva Couto P; Takeuchi Y; Rafiq QA; Jackson NB; Rayat ACME
Mol Ther Methods Clin Dev; 2024 Jun; 32(2):101264. PubMed ID: 38827249
[TBL] [Abstract][Full Text] [Related]
7. Benchmarking of Scale-X Bioreactor System in Lentiviral and Adenoviral Vector Production.
Leinonen HM; Lepola S; Lipponen EM; Heikura T; Koponen T; Parker N; Ylä-Herttuala S; Lesch HP
Hum Gene Ther; 2020 Mar; 31(5-6):376-384. PubMed ID: 32075423
[TBL] [Abstract][Full Text] [Related]
8. Optimization of lentiviral vector production using polyethylenimine-mediated transfection.
Tang Y; Garson K; Li L; Vanderhyden BC
Oncol Lett; 2015 Jan; 9(1):55-62. PubMed ID: 25435933
[TBL] [Abstract][Full Text] [Related]
9. Advancing a rapid, high throughput screening platform for optimization of lentivirus production.
Gopal S; Osborne AE; Hock L; Zemianek J; Fang K; Gee G; Ghosh R; McNally D; Cramer SM; Dordick JS
Biotechnol J; 2021 Oct; 16(10):e2000621. PubMed ID: 34260824
[TBL] [Abstract][Full Text] [Related]
10. Pseudorabies virus production using a serum-free medium in fixed-bed bioreactors with low cell inoculum density.
Nie J; Sun Y; Peng F; Han F; Yang Y; Liu X; Liu C; Li Y; Bai Z
Biotechnol Lett; 2020 Dec; 42(12):2551-2560. PubMed ID: 32816175
[TBL] [Abstract][Full Text] [Related]
11. Transient Lentiviral Vector Production Using a Packed-Bed Bioreactor System.
McCarron A; Donnelley M; McIntyre C; Parsons D
Hum Gene Ther Methods; 2019 Jun; 30(3):93-101. PubMed ID: 31084376
[TBL] [Abstract][Full Text] [Related]
12. Assessment of packed bed bioreactor systems in the production of viral vaccines.
Rajendran R; Lingala R; Vuppu SK; Bandi BO; Manickam E; Macherla SR; Dubois S; Havelange N; Maithal K
AMB Express; 2014; 4():25. PubMed ID: 24949260
[TBL] [Abstract][Full Text] [Related]
13. Comparison of different bioreactor systems for the production of high titer retroviral vectors.
Merten OW; Cruz PE; Rochette C; Geny-Fiamma C; Bouquet C; Gonçalves D; Danos O; Carrondo MJ
Biotechnol Prog; 2001; 17(2):326-35. PubMed ID: 11312711
[TBL] [Abstract][Full Text] [Related]
14. Development of a scalable process for high-yield lentiviral vector production by transient transfection of HEK293 suspension cultures.
Ansorge S; Lanthier S; Transfiguracion J; Durocher Y; Henry O; Kamen A
J Gene Med; 2009 Oct; 11(10):868-76. PubMed ID: 19618482
[TBL] [Abstract][Full Text] [Related]
15. Scale-up and manufacturing of clinical-grade self-inactivating γ-retroviral vectors by transient transfection.
van der Loo JC; Swaney WP; Grassman E; Terwilliger A; Higashimoto T; Schambach A; Baum C; Thrasher AJ; Williams DA; Nordling DL; Reeves L; Malik P
Gene Ther; 2012 Mar; 19(3):246-54. PubMed ID: 21753795
[TBL] [Abstract][Full Text] [Related]
16. Process Development of Adenoviral Vector Production in Fixed Bed Bioreactor: From Bench to Commercial Scale.
Lesch HP; Heikkilä KM; Lipponen EM; Valonen P; Müller A; Räsänen E; Tuunanen T; Hassinen MM; Parker N; Karhinen M; Shaw R; Ylä-Herttuala S
Hum Gene Ther; 2015 Aug; 26(8):560-71. PubMed ID: 26176404
[TBL] [Abstract][Full Text] [Related]
17. Upstream process optimization and micro- and macrocarrier screening for large-scale production of the oncolytic H-1 protoparvovirus.
Wohlfarth D; Frehtman V; Müller M; Vogel M; Phan LMP; Brunecker A; Leuchs B
Appl Microbiol Biotechnol; 2021 Dec; 105(24):9113-9124. PubMed ID: 34782922
[TBL] [Abstract][Full Text] [Related]
18. Scalable Lentiviral Vector Production Using Stable HEK293SF Producer Cell Lines.
Manceur AP; Kim H; Misic V; Andreev N; Dorion-Thibaudeau J; Lanthier S; Bernier A; Tremblay S; Gélinas AM; Broussau S; Gilbert R; Ansorge S
Hum Gene Ther Methods; 2017 Dec; 28(6):330-339. PubMed ID: 28826344
[TBL] [Abstract][Full Text] [Related]
19. Production of Lentiviral Vectors Using Suspension Cells Grown in Serum-free Media.
Bauler M; Roberts JK; Wu CC; Fan B; Ferrara F; Yip BH; Diao S; Kim YI; Moore J; Zhou S; Wielgosz MM; Ryu B; Throm RE
Mol Ther Methods Clin Dev; 2020 Jun; 17():58-68. PubMed ID: 31890741
[TBL] [Abstract][Full Text] [Related]
20. Exploring nutrient supplementation and bioprocess optimization to improve the production of lentiviral vectors in serum-free medium suspension cultures.
Vaz TA; Rodrigues AF; Coroadinha AS
Biotechnol J; 2024 Jan; 19(1):e2300212. PubMed ID: 37903159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
